DNLI - Denali to get $25M milestone as Sanofi begins dosing in multiple sclerosis study

• Denali Therapeutics ( NASDAQ: DNLI ) said it will receive a a milestone payment of $25M as Sanofi ( NASDAQ: SNY ) began dosing in a phase 2 trial of SAR443820 (DNL788) to treat patients with multiple sclerosis.
• SAR443820 is a central nervous system (CNS) penetrant investigational small molecule inhibitor of RIPK1, Denali noted.
• "SAR443820 has demonstrated robust target engagement and CNS penetration at doses that were generally well tolerated in Phase 1 studies in healthy volunteers, and we are eager to learn more from this Phase 2 study of SAR443820 in multiple sclerosis as we strive to bring innovative therapies to people with unmet medical needs," said Nazem Atassi, Global Head of Early Neurology Development at Sanofi.
• The companies had entered entered a broad partnership in 2018 for the global development and commercialization of CNS-penetrant and peripherally restricted RIPK1 inhibitors.

For further details see: